奥美医疗(002950) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥830,658,090.81, a decrease of 0.31% compared to the same period last year, and a year-to-date revenue of ¥2,327,252,559.38, down 24.65% year-on-year [4]. - Net profit attributable to shareholders for Q3 2021 was ¥91,362,715.90, a decline of 63.09%, with a year-to-date net profit of ¥329,132,304.17, down 65.69% [4]. - The basic earnings per share for Q3 2021 was ¥0.1443, reflecting a decrease of 63.09% compared to the same period last year [4]. - Total operating revenue for the current period is $2,327,252,559.38, down from $3,088,744,908.97 in the previous period, representing a decrease of approximately 24.6% [20]. - Net profit for the current period is $330,867,284.85, a decline of 65.5% compared to $960,718,427.09 in the same period last year [21]. - Basic earnings per share decreased to $0.5197 from $1.5146, reflecting a drop of approximately 65.7% [22]. - The total comprehensive income for the current period is $323,648,414.38, down from $942,347,156.76 in the previous period, a decrease of about 65.6% [22]. Assets and Liabilities - The company's total assets at the end of Q3 2021 were ¥4,878,627,077.32, an increase of 0.46% from the end of the previous year [5]. - Current assets decreased to CNY 2,211,661,598.31 from CNY 2,836,267,822.98, representing a decline of approximately 22% [16]. - Total liabilities increased to CNY 2,209,997,979.88 from CNY 1,932,969,618.30, marking an increase of approximately 14% [18]. - Total equity decreased to CNY 2,668,629,097.44 from CNY 2,923,110,846.62, a decline of approximately 9% [18]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥239,857,506.40, down 79.31% compared to the same period last year [4]. - Cash flow from operating activities generated a net amount of $239,857,506.40, significantly lower than $1,159,186,199.55 in the previous period [25]. - In Q3 2021, the net cash flow from financing activities was -313,448,681.28 CNY, compared to a positive 328,114,054.69 CNY in the same period last year [26]. - Total cash and cash equivalents at the end of Q3 2021 were 288,406,450.62 CNY, down from 837,610,741.62 CNY at the end of Q3 2020 [26]. Investments and Expenses - Research and development expenses increased by 17.82% to ¥58,101,424.18, indicating a focus on innovation [10]. - The company reported a significant increase in long-term equity investments by 88.36% to ¥741,452,100.48, reflecting increased external investments [10]. - The company experienced a 77.85% decrease in cash and cash equivalents, totaling ¥288,406,450.62, primarily due to profit distribution and increased investments [10]. - Cash inflow from investment activities totaled $1,948,559,246.47, compared to $1,442,324,531.71 in the previous period, indicating an increase of about 35.2% [25]. - Cash outflow from investment activities increased to $2,889,780,601.20 from $2,328,805,064.68, representing a rise of approximately 24% [25]. Shareholder Information - The number of common shareholders at the end of the reporting period was 51,122 [13]. - The company received government subsidies amounting to ¥68,463,898.47, an increase of 77.56% compared to the previous year [10]. Other Information - The company did not undergo an audit for the Q3 2021 report [27]. - The new leasing standards were not applicable for the financial statements in 2021 [27].